56649-48-0

Usage

Uses

Used in Pharmaceutical Industry:
(R)-(+)-1-(1-PHENYLETHYL)-1H-IMIDAZOLE-5-CARBOXYLIC ACID is used as a chiral building block for the synthesis of various pharmaceutical compounds. Its unique stereochemistry and structural features make it a valuable intermediate in the development of new drugs with improved efficacy and selectivity.
Used in Chemical Research:
In the field of chemical research, (R)-(+)-1-(1-PHENYLETHYL)-1H-IMIDAZOLE-5-CARBOXYLIC ACID serves as a key compound for studying the effects of stereochemistry on biological activity. It can be used to investigate the interactions between chiral molecules and their targets, such as enzymes or receptors, which is crucial for understanding the mechanisms of action of potential drugs.
Used in Material Science:
The structural properties of (R)-(+)-1-(1-PHENYLETHYL)-1H-IMIDAZOLE-5-CARBOXYLIC ACID may also find applications in material science, particularly in the development of novel materials with specific optical, electronic, or mechanical properties. Its imidazole and phenylethyl moieties could be exploited to create new materials with tailored characteristics for various applications.

Upstream product

• 33125-97-2 etomidate 
• 53188-20-8 Etomidate hydrochloride 
• 61045-91-8 (R)-Metomidate 

Downstream Products

• 1198154-79-8 MOC-(R)-etomidate hydrochloride 
• 1217528-70-5 2-(2-bromoethoxy)ethyl 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylate 
• 1217528-71-6 2-[2-(2-chloroethoxy)ethoxy]ethyl 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylate 
• 1198154-78-7 methoxycarbonyl etomidate 

Relevant academic research and scientific papers

2-(3-Methyl-3H-diaziren-3-yl) ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: A derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels

To locate general anesthetic binding sites on ligand-gated ion channels, a diazirine derivative of the potent intravenous anesthetic, R-(+)-etomidate (2-ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate), has been synthesized and characterized. R-(+)-Azi

Design, synthesis and evaluation of 1-benzyl-1H-imidazole-5-carboxamide derivatives as potent TGR5 agonists

TGR5 is emerging as an important and promising target for the treatment of diabetes, obesity and other metabolic syndromes. A series of novel 1-benzyl-1H-imidazole-5-carboxamide derivatives was designed, synthesized and evaluated in vitro and in vivo. The

Ketone-substituted heterocyclic compound and anesthetic effect thereof

The invention discloses a ketone-substituted heterocyclic compound and an anesthetic effect thereof. Specifically provided are a compound represented by formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a deuterated derivative thereof. The ketone-substituted heterocyclic compound provided by the invention has a good central nervous system inhibition effect, can generate sedative, hypnotic and/or general anesthesia effects, and can control the epilepsy persistent state; the ketone-substituted heterocyclic compound also has the characteristics of quick response and quick recovery while maintaining excellent anesthetic activity; meanwhile, the ketone-substituted heterocyclic compound has almost no inhibition effect on the adrenal cortex function, has small sideeffects, solves the technical problems in the field, and provides a new choice for clinically screening and/or preparing sedative, hypnotic and/or general anesthesia medicines and medicines for controlling the epilepsy persistent state.

SUBSTITUTED IMIDAZOLECARBOXYLATE DERIVATIVES AND THE USE THEREOF

A compound is shown in formula (I). The derivatives of the compound include a stereoisomer, a pharmaceutically acceptable salt, a solvate, a prodrug, a metabolite, a deuterated derivative. The compound is a structurally novel substituted imidazole formate derivative. Substituted imidazole formate derivatives are used in preparing a drug with sedative, hypnotic and/or anesthetic effects, as well as a drug that can control the state of epilepsy. The compound has a good inhibitory effect on the central nervous system, and provides a new option for clinical screening of and/or preparation of a drug with sedative, hypnotic and/or anesthetic effects and controlling the state of epilepsy.

Phenylethyl imidazole derivative and application thereof

The invention belongs to the technical field of medicines, and provides a novel phenylimidazole amide derivative shown as a general formula (I) (See the specification) and a geometrical isomer or pharmaceutically acceptable salt, hydrate, solvate and prodrug thereof, and preparation methods thereof. The compound can activate the activity of TGR5 and can be used for treating or preventing diseasesrelated to TGR5 activity regulation.

Etomidate derivative and preparation method thereof

The invention discloses an etomidate analogue shown in a formula (I). The analogue which needs to be developed in the field keeps beneficial performances (such as quick action, almost no influences onblood pressure and high therapeutic index) of etomidate

Metabolite-inactive etomidate analogues alleviating suppression on adrenal function in Beagle dogs

Owing to rapid generation in body, the metabolites of etomidate softdrug are able to accumulate in either the brain or periphery and subsequently affect the recovery from anaesthesia or cause corticosteroid suppression. This study was designed to investigate the ability of two etomidate analogues (ET-26, ET-42) with inactive metabolites to provide anaesthesia with lesser corticosteroid suppression. The 50% effective dose (ED50) of ET-26, ET-42, Etomidate, MOC-ET (an etomidate softdrug) and CPMM (an improved etomidate softdrug) required to induce anaesthesia intravenously in Beagle dogs were 1.44 mg/kg, 0.72 mg/kg, 0.43 mg/kg 23.12 mg/kg and 0.59 mg/kg, respectively. After adrenocorticotropic hormone (ACTH) stimulation, the serum concentrations of cortisol and corticosterone in the ET-26, ET-42 and CPMM groups were similar to those of controls, and significantly higher than those of the etomidate and MOC-etomidate groups (P 50 = 1.44 mg/kg) and ET-42 (ED50 = 0.72 mg/kg) were determined. Both analogues can significantly reduce the corticosteroid suppression in vivo. Metabolite-inactive etomidate derivatives with slow metabolism might provide a novel strategy to improve Etomidate associated corticosteroid suppression.

Anesthetic compounds and related methods of use

Provided herein are compounds according to formula (I): Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.

ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE

Provided herein are compounds according to formula (I): Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.

ETOMIDATE ANALOGUES WITH IMPROVED PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES

The invention is directed to compounds according to formula (I): where R1 is L1C(O)OT or L1C(O)OL2C(O)OT; R2 is a substituted or unsubstituted C1-C10 alkyl, C2-C1